- Home
- AUDC vs AARD Comparison
AUDC vs AARD Comparison
Compare AUDC & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUDC | AARD |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 297.2M |
| IPO Year | 1999 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AUDC | AARD |
|---|---|---|
| Price | $8.36 | $15.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $11.67 | ★ $31.11 |
| AVG Volume (30 Days) | 73.0K | ★ 214.5K |
| Earning Date | 02-03-2026 | 02-14-2026 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | ★ 15.76 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $244,553,000.00 | N/A |
| Revenue This Year | $2.98 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | ★ 0.15 | N/A |
| 52 Week Low | $8.01 | $4.88 |
| 52 Week High | $12.72 | $19.58 |
Technical Indicators
Market Signals| Indicator | AUDC | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 64.95 |
| Support Level | $8.71 | $14.25 |
| Resistance Level | $8.94 | $16.00 |
| Average True Range (ATR) | 0.20 | 0.93 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 3.41 | 82.00 |
Price Performance
Historical ComparisonAbout AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.